• Rafael Golpe, Luis A Pérez-de-Llano, David Dacal, Hector Guerrero-Sande, Beatriz Pombo-Vide, Pablo Ventura-Valcárcel, and Lugo Covid-19 team.
• Servicio de Neumología, Hospital Universitario Lucus Augusti, Lugo, Spain. Electronic address: rafagolpe@gmail.com.
• Med Clin (Barc). 2020 Dec 11; 155 (11): 488-490.

IntroductionThere is controversy concerning the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II type-I receptor blockers (ARB) for treating hypertensive patients with Covid-19. It has been hypothesized that these drugs might increase the risk of severe Covid-19, but some authors suggested that blocking the renin-angiotensin system might actually decrease this risk.MethodsRetrospective cohort study of all the consecutive hypertensive patients with confirmed SARS-CoV-2 infection in a health area. The outcome variable was hospitalization because of severe Covid-19.Results539 subjects were diagnosed of SARS-CoV-2 infection. Of these, 157 (29.1%) had hypertension and were included in the study. Sixty-nine cases (43.9%) were hospitalized because of severe Covid-19. In multivariable analysis older age, diabetes and hypertensive myocadiopathy were related to a higher risk of hospital admission. ARB treatment was associated with a significantly lower risk of hospitalization (HR: 0.29, 95% CI: 0.10 - 0.88). A similar albeit not significant trend was observed for ACEI.ConclusionARB or ACEI treatment was not associated with a worse clinical outcome in consecutive hypertensive patients infected by SARS-CoV-2.Copyright © 2020 Elsevier España, S.L.U. All rights reserved.

22 keywords...

hide…